Empasiprubart for teenagers with chronic inflammatory demyelinating polyneuropathy
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new medicine called empasiprubart for teenagers with a specific type of CIDP, a nerve condition that causes weakness and numbness. The trial aims to find the right dose and see if it's safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 17 years old.
- You must have a confirmed diagnosis of CIDP (a nerve disease causing weakness and numbness) by a doctor, and it must be one of these types: typical (most common), motor (muscle weakness), multifocal (asymmetric), focal (limited to one area), or distal (starting in the feet).
- You must not have 'possible' CIDP (where doctors are not sure yet), or sensory-predominant CIDP (mainly affecting feeling rather than strength).
- You must not have another autoimmune disease or other medical condition that could interfere with the study or put you at extra risk.
- You must not have previously used any long-acting immunomodulatory treatment (a type of medicine that changes your immune response for a long time).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
This program provides early access to an investigational medication called efgartigimod for adults with CIDP who haven't responded well to usual treatments. The drug aims to reduce the immune attack on nerves and may help manage symptoms when other options fail.
This study tests a new medicine called empasiprubart in adults with multifocal motor neuropathy (MMN), a rare condition affecting nerve function. The trial uses ultrasound to see if the medicine can help reduce nerve thickening and improve symptoms.
This trial tests whether a new medicine called imeroprubart can help people with CIDP, a nerve condition causing weakness and numbness. It may provide an alternative to current treatments like steroids or immunoglobulin therapy.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.